Anti-RBD scFv (CB6)-Fc mRNA-LNP

The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. Within the spike protein, there is a receptor-binding domain, considered a key viral element that allows the coronavirus to dock with target cells. Mutations in the RBD appear in new variants, such as the Delta variant with 2 mutations and the Omicron variant with 15 mutations, posing challenges for pandemic vaccination. Studies have revealed that a large number of antibodies show neutralization activity by targeting the RBD of COVID-19 viruses. The CB6, a human monoclonal antibody obtained from a patient convalescing from COVID-19 has been identified to target the RBD of SARS-CoV-2 with an ability to neutralize the pandemic viruses.
This product is designed as a tool for the delivery and expression of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-RBD (CB6) scFv/CD3 mutant Fc in this product is approximately 70 kD and consists of anti-RBD (CB6) scFv (single-chain variable fragment), mutant human Fc and CD3ze signaling domains. The full-length amino acid sequence of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA-LNP product is available upon request.